PhaseBio Pharmaceuticals Inc

-0.03 (-0.78%)
Earnings Announcements

Phasebio Reports Q4 And FY20 Financial Results

Published: 03/15/2021 12:20 GMT
PhaseBio Pharmaceuticals Inc (PHAS) - Phasebio Reports Fourth-quarter and Full-year 2020 Financial Results and Recent Business Highlights.
Qtrly Loss per Share $1.03.
Q4 Earnings per Share View $-0.71 -- Refinitiv Ibes Data (analyst estimates).
Cash and Cash Equivalents at Dec 31, 2020 Were $28.1 Million Versus $74.0 Million at Dec 31, 2019.
Revenue is expected to be $0.25 Million
Adjusted EPS is expected to be -$0.60

Next Quarter Revenue Guidance is expected to be $1.71 Million
Next Quarter EPS Guidance is expected to be -$0.52

More details on our Analysts Page.